Header Logo

Connection

John Somberg to Drug Evaluation

This is a "connection" page, showing publications John Somberg has written about Drug Evaluation.
Connection Strength

0.364
  1. International symposium on drug development. Am J Ther. 1999 Sep; 6(5):289.
    View in: PubMed
    Score: 0.173
  2. Biologic problems. Am J Ther. 2002 Nov-Dec; 9(6):471.
    View in: PubMed
    Score: 0.054
  3. Class effects of pharmaceuticals and therapeutic interchangeability. Am J Ther. 2001 Jul-Aug; 8(4):221-2.
    View in: PubMed
    Score: 0.049
  4. Encainide: a new and potent antiarrhythmic. Am Heart J. 1987 Oct; 114(4 Pt 1):826-35.
    View in: PubMed
    Score: 0.019
  5. Long-term lorcainide therapy in patients with ventricular tachycardia. Am Heart J. 1985 Jan; 109(1):33-40.
    View in: PubMed
    Score: 0.016
  6. Lorcainide therapy for the high-risk patient post myocardial infarction. Am J Cardiol. 1984 Aug 13; 54(4):37B-42B.
    View in: PubMed
    Score: 0.015
  7. Evaluation of lorcainide in patients with symptomatic ventricular tachycardia. Am J Cardiol. 1984 Aug 13; 54(4):43B-48B.
    View in: PubMed
    Score: 0.015
  8. Comparison of noninvasive arrhythmia induction techniques with electrophysiologic studies and evaluation of lorcainide in patients with symptomatic ventricular tachycardia. Am J Cardiol. 1984 Aug 13; 54(4):49B-54B.
    View in: PubMed
    Score: 0.015
  9. Pharmacokinetics of oral cibenzoline in arrhythmia patients. Clin Pharmacokinet. 1985 Mar-Apr; 10(2):178-86.
    View in: PubMed
    Score: 0.004
  10. Cibenzoline plasma concentration and antiarrhythmic effect. Clin Pharmacol Ther. 1984 Mar; 35(3):307-16.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.